AVBP SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving ArriVent BioPharma
AVBP was down 56.7% before the opening bell and traded as low as $12.09 after ArriVent disclosed that its Phase 3 FURVENT trial of firmonertinib missed its primary endpoint. An investigation into potential securities law violations is underway. NEW YORK, Oct. 7, 2026 /PRNewswire/ --...
Covered in this story
Call it yourself
No calls on $AVBP yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Arrivent Biopharma Inc →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.